Are biosimilars similar enough?

Paul Cornes, MD from the University Hospital Bristol NHS Foundation Trust, Bristol, UK takes us through the concept of batch variation in branded biologics, how it has been justified by regulators and trusted by doctors, and how the same principles and strict rules have been put in place to justify the manufacture of biosimilar drugs.

Share this video